Science in Focus: Circulating Tumour DNA as a Liquid Biopsy

Clinical Oncology

Volumn 28, Issue 12, 2016, Pages 735-738

  O'Leary, B ^a   Turner, N C ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CIRCULATING TUMOR DNA; DNA; UNCLASSIFIED DRUG;

CANCER PATIENT; CANCER REGRESSION; CANCER RESISTANCE; CELL FREE SYSTEM; CIRCULATING TUMOR CELL; DNA DETERMINATION; EARLY CANCER DIAGNOSIS; EDITORIAL; GENE MUTATION; GENETIC HETEROGENEITY; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MINIMAL RESIDUAL DISEASE; PHASE 4 CLINICAL TRIAL (TOPIC); POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TUMOR BIOPSY;

EID: 84994910567     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2016.08.007     Document Type: Editorial

References (28)

1. [1] Mandel, P., Metais, P., Les acides nucléiques du plasma sanguin chez l'homme. C R Seances Soc Biol Fil 142:3–4 (1948), 241–243.
2. [2] Leon, S.A., Sklaroff, D.M., Yaros, M.J., Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 37 (1977), 646–650.
3. [3] Lander, E.S., Linton, L.M., Birren, B., et al. Initial sequencing and analysis of the human genome. Nature 409:6822 (2001), 860–921.
4. [4] Venter, J.C., Adams, M.D., Myers, E.W., et al. The sequence of the human genome. Science 291:5507 (2001), 1304–1351.
5. [5] Lo, Y.M.D., Corbetta, N., Chamberlain, P.F., et al. Presence of fetal DNA in maternal plasma and serum. Lancet 350:9076 (1997), 485–487.
6. [6] Jahr, S., Hentze, H., Englisch, S., et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 61:4 (2001), 1659–1665.
7. [7] Snyder, M.W., Kircher, M., Hill, A.J., Daza, R.M., Shendure, J., Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin. Cell 164:1 (2016), 57–68.
8. [8] Diehl, F., Schmidt, K., Choti, M.A., et al. Circulating mutant DNA to assess tumor dynamics. Nat Med 14:9 (2008), 985–990.
9. [9] Barra, G.B., Santa Rita, T.H., Vasques, JdA., Chianca, C.F., Nery, L.F.A., Costa, S.S.S., EDTA-mediated inhibition of DNases protects circulating cell-free DNA from ex vivo degradation in blood samples. Clin Biochem 48:15 (2015), 976–981.
10. [10] Kang, Q., Henry, N.L., Paoletti, C., et al. Comparative analysis of circulating tumor DNA stability In K3EDTA, Streck, and CellSave blood collection tubes. Clin Biochem, 2016 Apr 27 pii: S0009-9120(16)30040-6, http://dx.doi.org/10.1016/j.clinbiochem.2016.03.012 [Epub ahead of print].
11. [11] Diaz, L.A., Bardelli, A., Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol 32 (2014), 579–586.
12. [12] Diehl, F., Li, M., Dressman, D., et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci USA 102:45 (2005), 16368–16373.
13. [13] Newman, A.M., Lovejoy, A.F., Klass, D.M., et al. Integrated digital error suppression for improved detection of circulating tumor DNA. Nat Biotechnol 34:5 (2016 May), 547–555 http://dx.doi.org/10.1038/nbt.3520 [Epub 2016 Mar 28].
14. [14] Schwaederle, M., Husain, H., Fanta, P.T., et al. Use of liquid biopsies in clinical oncology: pilot experience in 168 patients. Clin Cancer Res, 2016 May 16 clincanres-0318, http://dx.doi.org/10.1158/1078-0432.CCR-16-0318.
15. [15] Zill, O.A., Banks, K.C., Nagy, R.J., et al. Somatic genomic landscape of over 15,000 patients with advanced-stage cancer from clinical next-generation sequencing analysis of circulating tumor DNA. J Clin Oncol, 34(suppl.), 2016 abstract LBA11501.
16. [16] Douillard, J.Y., Ostoros, G., Cobo, M., et al. First-line gefitinib in caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study. Br J Cancer 110:1 (2014), 55–62.
17. [17] Zheng, D., Ye, X., Zhang, M.Z., et al. Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance. Sci Reports, 6, 2016, 20913.
18. [18] Fribbens, C., O'Leary, B., Kilburn, L., et al. Plasma ESR1 mutations and the treatment of estrogen receptor–positive advanced breast cancer. J Clin Oncol, 2016 Jun 6 JCO673061.
19. [19] Romanel, A., Tandefelt, D.G., Conteduca, V., et al. Plasma AR and abiraterone-resistant prostate cancer. Sci Transl Med, 7(312), 2015, 312re10.
20. [20] Siravegna, G., Mussolin, B., Buscarino, M., et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med 21:7 (2015), 795–801.
21. [21] Murtaza, M., Dawson, S.J., Pogrebniak, K., et al. Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer. Nat Commun, 6, 2015, 8760.
22. [22] Bettegowda, C., Sausen, M., Leary, R.J., et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med, 6(224), 2014, 224ra24.
23. [23] Garcia-Murillas, I., Schiavon, G., Weigelt, B., et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med, 7(302), 2015 302ra133–302ra133.
24. [24] Reinert, T., Schøler, L.V., Thomsen, R., et al. Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery. Gut, 65 (4), 2016 Apr 1, 625–634.
25. [25] Olsson, E., Winter, C., George, A., et al. Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease. EMBO Mol Med 7:8 (2015), 1034–1047.
26. [26] Roschewski, M., Dunleavy, K., Pittaluga, S., et al. Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. Lancet Oncol 16:5 (2015), 541–549.
27. [27] Amant, F., Verheecke, M., Wlodarska, I., et al. Presymptomatic identification of cancers in pregnant women during noninvasive prenatal testing. JAMA Oncol 1:6 (2015), 814–819.
28. [28] Martincorena, I., Roshan, A., Gerstung, M., et al. High burden and pervasive positive selection of somatic mutations in normal human skin. Science 348:6237 (2015), 880–886.